This review article looks at the epidemiology of Lambert–Eaton myasthenic syndrome (LEMS), clinical discrimination of small-cell lung carcinoma (SCLC)-related LEMS from non-tumour LEMS, pathophysiology, and current treatment options, with the aim of improving diagnosis, accelerating screening times for SCLC, and optimising treatment.